The frequency and profile of drug treatment in subjects with dyslipidemias and cardimetabolic diseases in an urban russian population older then 55 years

Aim      To analyze frequency and profile of the lipid-lowering therapy (LLT) in patients with dyslipidemia (DLP) and cardiometabolic diseases (CMD) in a population sample aged 55-84 years at the current time (2015–2017).

Material and methods  Despite guidelines on DLP treatment and the availability of effective and safe lipid-lowering drugs, control of DPL in primary and secondary prevention of cardiovascular diseases (CVD) is insufficient. Knowledge of the level of pharmaceutical correction of DLP in the Russian population is limited; it requires an LLT assessment in various regions and in a wide age range, and a regular monitoring taking into account changing approaches to the correction of DLP. A random population of men and women aged 55–84 years (n=3 896) was evaluated in Novosibirsk in 2015–2017 (project HAPIEE). A joint DLP category was established as low-density lipoprotein cholesterol (LDL-C) ≥3.0 mmol/l, or total cholesterol (TC) ≥5.0 mmol/l, or triglycerides (TG) ≥1.7 mmol/l, or LLT. The combined group of DLP and CMD included ischemic heart disease (IHD), type 2 diabetes mellitus (DM2), and DLP. Regular LLD treatment for the recent 12 months, excluding the dosage of medicines, was assessed using the Anatomic Therapeutic Chemical (ATC) classification. The conditional control of serum lipids was taken as the achievement of LDL-C <3.0 mmol/l, TC <5.0 mmol/l, and TG <1.7 mmol/l.

Results In the study sample, the total prevalence of DLP and CMD was 88 % (82.8 % for men and 91.3 % for women, p<0.001). 48.3% of patients in the IHD group, 35.0% in the DM2 group, 29.4% in the DLP group, and 32.8% in the CMD group took LLT. Control of serum lipids was achieved in 18.3% (37.9 % of patients on LLT) of patients with IHD; 9 % (25.6 % of patients on LLT) of patients with DM2; 7.3 % (24.8 % of patients on LLT) of patients with DLP; and 9.0 % (27.6 % of patients on LLTсреди) in the DLP and CMD group. Women with DM2 and DLP more frequently achieved lipid control than men (p<0.001). 98.7 % of study participants took statins as LLT.

Conclusion      In the sample of urban population aged 55–84 years in 2015–2017, 90 % of patients had DLP or CMD, and at least ¾ of them required blood lipid control. The lipid control was achieved in every fifth IHD patient and in approximately 40% of those who took LLT. For DM2 or DLP patients, the lipid control was achieved in every tenth patient and in approximately 25% of those receiving LLT. Frequency of lipid control in IHD patients was comparable for men and women; in DM2 and DLP, men less frequently achieved the lipid control than women. About 70% of patients in the combined DLP and CMD group and more than 50% of IHD patients did not take LLT, which considerably contributed to the insufficient lipid control in primary and secondary prevention of atherosclerotic CVDs in this population.

1. Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe – epidemiological update 2015. European Heart Journal. 2015;36(40):2696–705. DOI: 10.1093/eurheartj/ehv428

2. Federal State Statistics Service. Russian statistical yearbook 2019. Statistical handbook. -M.: Rosstat;2019. - 708 p. https://rosstat.gov.ru/storage/mediabank/Ejegodnik_2019.pdf. ISBN 978-5-89476-473-3

3. Federal State Statistics Service. Natural movement of the population in the context of the subjects of the Russian Federation. 2019. https://www.gks.ru/free_doc/2019/demo/edn10-19.htm [Internet] 2019.

4. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111–88. DOI: 10.1093/eurheartj/ehz455

5. Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiology. 2017;2(1):47–54. DOI: 10.1001/jamacardio.2016.4052

6. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2017;38(32):2459–72. DOI: 10.1093/eurheartj/ehx144

7. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. The Lancet. 2005;366(9493):1267–78. DOI: 10.1016/S0140-6736(05)67394-1

8. Graham IM, Catapano AL, Wong ND. Current guidelines on prevention with a focus on dyslipidemias. Cardiovascular Diagnosis and Therapy. 2017;67(Suppl 1):S4–10. DOI: 10.21037/cdt.2017.04.04

9. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal. 2016;37(29):2315–81. DOI: 10.1093/eurheartj/ehw106

10. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281–344. DOI: 10.1016/j.atherosclerosis.2016.08.018

11. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143. DOI: 10.1161/CIR.0000000000000625

12. Kukharchuk V.V., Ezhov M.V., Sergienko I.V., Arabidze G.G., Bubnova M.G., Balakhonova T.V. et al. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat of atherosclerosis Russian recommendations VII revision. Atherosclerosis and dyslipidemia. 2020;1(38):7–40. DOI: 10.34687/2219-8202.JAD.2020.01.0002

13. Ezhov M.V., Sergienko I.V., Aronov D.M., Arabidze G.G., Akhmedzhanov N.M., Bazhan S.S. et al. Diagnostics and correction of lipid me tabolism disorders for the prevention and treatment of atherosclerosis. Revision VI. Atherosclerosis and Dyslipidemias. 2017;3(28):5–22.

14. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ et al. American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocrine Practice. 2017;23(Suppl 2):1–87. DOI: 10.4158/EP171764. APPGL

15. De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Ž, Rydén L et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135–46. DOI: 10.1016/j.atherosclerosis.2019.03.014

16. Shlyakhto E.V., Zvartau N.E., Villevalde S.V., Yakovlev A.N., Soloveva A.E., Alieva A.S. et al. Cardiovascular risk management system: prerequisites for developing, organization principles, target groups. Russian Journal of Cardiology. 2019;24(11):69–82. DOI: 10.15829/1560-4071-2019-11-69-82

17. de la Sierra A, Pintó X, Guijarro C, Miranda JL, Callejo D, Cuervo J et al. Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain. Advances in Therapy. 2015;32(10):944–61. DOI: 10.1007/s12325-015-0252-y

18. Pogosova N.V., Oganov R.G., Boytsov S.A., Ausheva A.K., Sokolova O.Yu., Kursakov A.A. et al. Monitoring the Secondary Prevention of Coronary Artery Disease in Europe and Russia: Results of the Russian Part of the International Multicenter Study EUROASPIRE IV. Kardiologiia. 2015;55(12):99–107.

19. Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European Journal of Preventive Cardiology. 2019;26(8):824–35. DOI: 10.1177/2047487318825350

20. American Heart Association. Prevalence and Number of US Adults Eligible for and Currently Using Statin Therapy by Race/Ethnicity (NHANES 2011-2014) – Health Metrics. 2018. [Internet] 2018. Available at: https://aha2017chme.wpengine.com/prevalence-andnumber-of-us-adults-eligible-for-and-currently-using-statin-therapyby-race-ethnicity-nhanes-2011-2014/

21. Gu Q, Paulose-Ram R, Burt VL, Kit BK. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS data brief. 2014;177:1–8. PMID: 25536410

22. Vega GL, Grundy SM. Current trends in non–HDL cholesterol and LDL cholesterol levels in adults with atherosclerotic cardiovascular disease. Journal of Clinical Lipidology. 2019;13(4):563–7. DOI: 10.1016/j.jacl.2019.05.012

23. Mefford MT, Rosenson RS, Deng L, Tanner RM, Bittner V, Safford MM et al. Trends in Statin Use Among US Adults With Chronic Kidney Disease, 1999–2014. Journal of the American Heart Association. 2019;8(2):e010640. DOI: 10.1161/JAHA.118.010640

24. Carroll MD, Fryar CD, Nguyen DT. Total and High-density Lipoprotein Cholesterol in Adults: United States, 2015-2016. NCHS data brief. 2017;290:1–8. PMID: 29155686

25. Muromtceva G.A., Kontsevaya A.V., Konstantinov V.V., Artamonova G.V., Gatagonova T. M., Duplyakov D.V. et al. The prevalence of noninfectious disease risk factors in the Russian population in 2012-2013. Results of the ESSE-RF study. Cardiovascular Therapy and Prevention. 2014;13(6):4–11. DOI: 10.15829/1728-8800-2014-6-4-11

26. Meshkov A.N., Ershova A.I., Deev A.D., Metelskaya V.A., Zhernakova Yu.V., Rotar O.P. et al. Distribution of lipid profile values in economically active men and women in Russian Federation: results of the esse-rf study for the years 2012-2014. Cardiovascular Therapy and Prevention. 2017;16(4):62–7. DOI: 10.15829/1728-8800-2017-4-62-67

27. Shalnova S.A., Deev A.D., Metelskaya V.A., Evstifeeva S.E., Rotar O.P., Zhernakova Yu.V. et al. Awareness and treatment specifics of statin therapy in persons with various cardiovasular risk: the study ESSE-RF. Cardiovascular Therapy and Prevention. 2016;15(4):29–37. DOI: 10.15829/1728-8800-2016-4-29-37

28. NCD Risk Factor Collaboration (NCD-RisC), Taddei C, Zhou B, Bixby H, Carrillo-Larco RM, Danaei G et al. Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020;582(7810):73–7. DOI: 10.1038/s41586-020-2338-1

29. Malyutina S.K., Shapkina М.Yu., Ryabikov A.N., Mazdorova E.V., Avdeeva Е.М., Shcherbakova L.V. et al. Characteristics of main drug therapy types in subjects with atrial fibrillation in population. Cardiovascular Therapy and Prevention. 2018;17(1):43–8. DOI: 10.15829/1728-8800-2018-1-43-48

30. Malyutina S.K., Mazdorova E.V., Shapkina М.Yu., Avdeeva Е.М., Maslacov N.A., Simonova G.I. et al. The profile of drug treatment in subjects aged over 50 years with hypertension in an urban russian population. Kardiologiia. 2020;60(3):21–9. DOI: 10.18087/cardio.2020.3.n948

31. Peasey A, Bobak M, Kubinova R, Malyutina S, Pajak A, Tamosiunas A et al. Determinants of cardiovascular disease and other non-communicable diseases in Central and Eastern Europe: Rationale and design of the HAPIEE study. BMC Public Health. 2006;6(1):255. DOI: 10.1186/1471-2458-6-255

32. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension. 2018;36(10):1953–2041. DOI: 10.1097/HJH.0000000000001940

33. Cardiovascular Survey Methods. Rose GA, editor -Genève: WHO;1984. - 188 p. ISBN 978-92-4-240056-4

34. Kalinina A.M., Shalnova S.A., Gambaryan M.G., Eganyan R.A., Muromtseva G.A., Bochkareva E.V. et al. Epidemiological methods for identifying the main chronic non-communicable diseases and risk factors during mass population surveys. Methodical guide. Edited by Prof. Boytsov S.A. - M.: GNICPM; 2015. - 96p. Av. at: https://gnicpm.ru/wp-content/uploads/2020/01/metodposobie_epid_metody_viyavleniya_hniz_pri_massovih_obsledovaniyah.pdf.

35. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European Heart Journal. 2013;34(39):3035–87. DOI: 10.1093/eurheartj/eht108

36. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDDs. [Internet] Available at: https://www.whocc.no/atc_ddd_index_and_guidelines/atc_ddd_index/

37. Boytsov S.A., Luk’yanov M.M., Yakushin S.S., Martsevich S.Yu., Vorobyov A.N., Zagrebelny A.V. et al. Cardiovascular diseases registry (RECVAZA): diagnostics, concomitant cardiovascular pathology, comorbidities and treatment in the real outpatient-polyclinic practice. Cardiovascular Therapy and Prevention. 2014;13(6):44–50. DOI: 10.15829/1728-8800-2014-6-44-50

38. Akhmedzhanov N.M., Nebieridze D.V., Safaryan A.S., Vygodin V.A., Shuraev A.Yu., Tkacheva O.N. et al. Analysis of hypercholesterolemia prevalence in the outpatient practice (according to the ARGO study): part I. Rational Pharmacotherapy in Cardiology. 2015;11(3):253–60. DOI: 10.20996/1819-6446-2015-11-3-253-260

39. Peters SAE, Muntner P, Woodward M. Sex Differences in the Prevalence of, and Trends in, Cardiovascular Risk Factors, Treatment, and Control in the United States, 2001 to 2016. Circulation. 2019;139(8):1025–35. DOI: 10.1161/CIRCULATIONAHA.118.035550

40. Ershova A.I., Meshkov A.N., Yakushin S.S., Loukianov M.M., Moseychuk K.A., Martsevich S.Yu. et al. Diagnosis and treatment of patients with severe hypercholesterolemia in real outpatient practice (according to the RECVASA registry). Rational Pharmacotherapy in Cardiology. 2014;10(6):612–6. DOI: 10.20996/1819-6446-2014-10-6-612-616